Theranostics 2011; 1:30-47. doi:10.7150/thno/v01p0030

Review

Why Integrin as a Primary Target for Imaging and Therapy

Gang Niu1,2, Xiaoyuan Chen2 Corresponding address

1. Imaging Sciences Training Program, Radiology and Imaging Sciences, Clinical Center and National Institute Biomedical Imaging and Bioengineering, NIH
2. Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Niu G, Chen X. Why Integrin as a Primary Target for Imaging and Therapy. Theranostics 2011; 1:30-47. doi:10.7150/thno/v01p0030. Available from http://www.thno.org/v01p0030.htm

Abstract

Integrin-mediated cell adhesion is involved in many essential normal cellular and pathological functions including cell survival, growth, differentiation, migration, inflammatory responses, platelet aggregation, tissue repair and tumor invasion. 24 different heterodimerized transmembrane integrin receptors are combined from 18 different α and 8 different β subunits. Each integrin subunit contains a large extracellular domain, a single transmembrane domain and a usually short cytoplasmic domain. Integrins bind extracellular matrix (ECM) proteins through their large extracellular domain, and engage the cytoskeleton via their short cytoplasmic tails. These integrin-mediated linkages on either side of the plasma membrane are dynamically linked. Thus, integrins communicate over the plasma membrane in both directions, i.e., outside-in and inside-out signaling. In outside-in signaling through integrins, conformational changes of integrin induced by ligand binding on the extracellular domain altered the cytoplasmic domain structures to elicit various intracellular signaling pathways. Inside-out signaling originates from non-integrin cell surface receptors or cytoplasmic molecules and it activates signaling pathways inside the cells, ultimately resulting in the activation/deactivation of integrins. Integrins are one of key family proteins for cell adhesion regulation through binding to a large number of ECM molecules and cell membrane proteins. Lack of expression of integrins may result in a wide variety of effects ranging from blockage in pre-implantation to embryonic or perinatal lethality and developmental defects. Based on both the key role they played in angiogenesis, leukocytes function and tumor development and easy accessibility as cell surface receptors interacting with extracellular ligands, the integrin superfamily represents the best opportunity of targeting both antibodies and small-molecule antagonists for both therapeutic and diagnostic utility in various key diseases so far.

Keywords: Integrin, inside-out signaling, outside-in signaling, cell adhesion molecule, angiogenesis.

1. INTRODUCTION

Adhesion of cells to the surrounding extracellular matrix (ECM) and to other cells is essential for tissue integrity, which have been crucial for the evolution from protozoans to metazoans. Integrin-mediated cell adhesion to ECM plays a central role in the formation and remodeling of tissues and organs in multicellular organisms [1-2]. Integrins mediate cell-to-cell and cell-to-ECM adhesion, providing adhesion for stationary cells, traction during cell movement and, importantly, the promotion of many signaling pathways that regulate diverse processes including proliferation, migration, cell survival, differentiation, tumor invasion and metastasis [3-4]. As a family of heterodimeric transmembrane receptors consisting of an α and a β subunit, 18 different α and 8 different β subunits are known in mammals, which can combine to 24 different integrin receptors [5-6]. Some subunits can combine with several different partners, adding to the structural complexity of integrin receptors. All these integrins can be segregated into two groups, one containing and the other lacking an extra von Willebrand factor type A domain (vWFA, known as αA or αI in integrins) in their α-subunits (Fig. 1). The composition and morphology of integrin-dependent adhesions (focal complexes/ podosomes, focal adhesions and fibrillar adhesions) vary with the cell type, matrix and integrin, and may switch from one adhesion contact to another, contributing to cell advancement, tissue remodeling and repair [7]. Based on their important biological and pathological function, integrins have been intensively investigated as imaging or therapy targets, which will be discussed in details in the following chapters of this book. The purpose of this chapter is to give an overall description of the structure, expression pattern, and biological/pathological function of various integrins.

 Figure 1 

The integrin superfamily. The integrins can be subdivided according to their β chains but note that some α chains can combine with several β chains. 24 different integrins are present in humans [8].

Theranostics Image (Click on the image to enlarge.)

2. INTEGRIN STRUCTURE

Each integrin subunit contains a large extracellular domain (N-terminus of >700 residues), a single transmembrane domain (>20 residues) and a usually short cytoplasmic domain (C-terminus of 13-70 residues) [9]. The I (inserted) domain is the most important integrin domain in ligand recognition [10]. For integrins, the αI domain presents in approximately half of all α subunits and the βI domain presents in all β subunits. The αI domain is the primary ligand binding region in the integrins which have this domain. Whereas in integrins which lack the α I domain, the binding site in the integrin “head” is formed by structural contributions of both the α and β chains [11]. αI is a GTPase-like domain in which the catalytic site at the apex is replaced with a conserved metal-ion-dependent adhesion site (MIDAS), which is occupied by a divalent cation. All of the integrin-ligand interfaces analyzed thus far have had at their center a coordinate bond between the integrin MIDAS and a carboxylate from the ligand and Mg2+ is the physiological metal that comprises integrin MIDAS [12]. αI domains have been crystallized in three distinct conformations, termed closed, intermediate, and open, with coordination of the metal in the MIDAS, arrangement of the β6-α7 loop, and axial disposition of the C-terminal α7-helix along the side of the I domain [13-14]. Change in coordination at the MIDAS of α I domains is coupled to backbone movements of loops that bear the coordinating residues to increase complementarities to ligands (Figure 2) [15].

In the α2 I domain-collagen triple helical peptide structure [16], the stiff collagen rod docks onto a shallow trench on top of the I domain, with MIDAS situated at the center, coordinated by a glutamate residue of collagen. Another major αI ligand class is comprised of cell surface molecule intercellular cell adhesion molecules (ICAMs). These are recognized by a β2 class of integrins that are exclusively expressed on leukocytes. This interaction is crucial in enabling leukocyte migration into sites of inflammation. Based on the structure of the ICAM-3-αL I domain solved by Song et al. [17], and the important structural determinants for the interaction are distributed across a rigid scaffold composed of a β sheet and a structurally constrained loop.

When present, αI domain is situated at the top of the heterodimer and forms clear protrusions [18-19], whereas the βI domain folds together intimately with the β-propeller domain of the a subunit, constituting half of the large globular head [20]. The crystal structure of the ectodomain from the αI domain-lacking integrin, αvβ3, was also determined in both unliganded (in the presence of Ca2+ or Mn2+) and ligand-bound states [11, 21]. As shown in Figure 3, αv consists of four domains: an N terminal seven-bladed β-propeller, an Ig-like Thigh domain and two large β-sandwich domains, Calf-1 and Calf-2. The β-subunit comprises an N-terminal cysteine-rich PSI (Plexin-Semaphorin-Integrin) domain in which an Ig-like “Hybrid” domain is inserted in its c-terminal loop (the Hybrid domain contains in turn an αA-like domain (βA domain) inserted between its two β-sheets). PSI is followed by four EGF-like domains and a membrane proximal novel tail domain (β-TD). The propeller and βA domains assemble into a “head” structure, which accounts for formation of the αβ heterodimer. The integrin head sits on top of an α and a β “legs”, formed respectively of the Thigh and Calf domains from the αV-subunit and the PSI, Hybrid, EGF1-4 and βTD domains from the β3-subunit [11].

The structure of liganded αvβ3 ectodomain was determined after diffusing the high affinity cyclic pentapeptide, cilengitide, which contains the prototypical Arg-Gly-Asp (cRGD), into preformed integrin crystals in the presence of 5 mM Mn2+. RGD inserts into a crevice between the propeller and βA domains, with the residues R and D side chains exclusively contacting the propeller and βA domains, respectively, and bringing these two domains closer together [21]. The activating inward movement of α1 helix and rearrangement of the F/α7 loop seen in liganded α I are also observed in liganded β I, leading to similar although much less dramatic changes in the three surface loops coordinating MIDAS and the SDL loop. Metal coordination at ADMIDAS changes significantly, such that it no longer locks the α1 helix to the F/α7 loop, allowing the activating movements in both. The inward movement of α1 carries ADMIDAS with it, moving it closer to MIDAS, thus helping stabilize the new metal ion at MIDAS [21].

 Figure 2 

Conformational change and transmission of allostery by α and β I domains. (a) The α I domain. Nonmoving segments of the backbone are shown as a gray worm. The moving segments of the backbone and the MIDAS metal ions are closed (gold) and open (cyan). The direction of movement is indicated with arrows. (b) The β I domain and its linkage to the hybrid and plexin/semaphorin/integrin (PSI) domain. Nonmoving segments of the β I backbone are shown as a gray worm. Moving segments and metal ions are color coded as shown. Directions of α1- and α7-helix movements are shown with arrows [18].

Theranostics Image (Click on the image to enlarge.)
 Figure 3 

Crystal structures of integrins αVβ3 and αIIbβ3. (a) The structure of αVβ3 in the bent conformation. The αV and β3 subunits are colored in green and red, respectively. (b) Superposition of liganded-open αIIbβ3 and unliganded-closed αVβ3 headpieces. The α and β subunits are colored in green and yellow in αVβ3 and in purple and light blue in αIIbβ3. Calcium and magnesium ions in αIIbβ3 only are gold and gray spheres, respectively [18].

Theranostics Image (Click on the image to enlarge.)

Crystal structures of the αvβ3 ectodomain in complex with the cyclic RGD peptide [21], as well as another RGD-type integrin (αIIbβ3) complexed with ligand mimetic compounds [22] have revealed that the minimal RGD set provides two essential anchorpoints: one is the Asp carboxylate, which coordinates directly the β MIDAS; the other is the Arg side chain (or basic moiety), which forms a salt bridge to an acidic residue in the b-propeller domain of the αv/αIIb subunit. In addition, these anchorpoints are located at the bottom of the narrow cleft or 'well', where the small ligand compounds are well accommodated, burying more than half of the molecular surface at the interface. αvβ3 integrin shows little preference in its choice among the many RGD-containing proteins. Surprisingly, even the strict RGD sequence requirement rule can be bent [23]. For example, cells from homozygous knock-in mice carrying the RGD→RGE mutation in fibronectin exhibited normal fibronectin assembly in an αvβ3-dependent manner [24]. This observation indicated that the positioning of both an acidic and basic residue in proper geometrical proximity is sufficient for meaningful affinity. The well-type pocket containing β MIDAS seems specifically designed to accommodate 'loop ligand'. Residues adjacent to RGD seem to provide some specificity toward certain integrins, both by making extra direct contacts and by changing the 'width' of the RGD segment [25-26].

Although α MIDAS and β MIDAS normally function in a tandem fashion in αI domain-containing integrins, they each could potentially engage two independent external ligands simultaneously. For example, semaphorin 7A, a GPI-anchored membrane protein that contains an RGD motif, was reported to promote axon outgrowth through b1 integrin(s), though the α subunit responsible for this activity was not determined [27]. Purified a1b1 does recognize semaphorin 7A in an RGD-dependent manner [28]. It is therefore tempting to speculate that RGD binds to the β MIDAS, leaving the α MIDAS unoccupied. Laminins are major basement membrane proteins composed of three different polypeptide chains, termed a, b, and g. Till date, five a, three b, and three g chains are known to make up at least 15 isoforms of heterotrimeric laminins in mammals [29]. It has been reported that integrins exhibited a distinct laminin isoform preference [30]. Mutational and antibody mapping studies have revealed that C-terminal laminin globular (LG) domains of the a chain, particularly LG1-3, are important for integrin recognition [31]. However, recombinant fragments corresponding to this region have not shown significant cell adhesion activity comparable to that of intact heterotrimeric laminins. Full integrin-binding activity of LG1-3 requires the heterotrimeric C-terminal portion of the coiled-coil domain, including the most distant C-terminal region of the b and g chains [32].

Accumulating evidence supported that the structure changes of integrins are the basis of the integrin signaling. Indeed, negative stain electron microscopy with image averaging of integrins has shown three overall conformations of the extracellular domain and these correspond to a low affinity, bent conformation (as in the αvβ3 structure), an intermediate affinity, extended form with a closed headpiece, and a high affinity, extended form with an open headpiece, which is induced by ligand mimetic compounds [22]. In integrins that lack the I-domain, the ligand binds directly to the β I-like domain, and causes a downward movement of its α7 helix, similarly to what was described above for the integrin α I-domains. This shift results in a swing-out movement of the β chain hybrid and PSI domains and these domains act as a rigid lever that transmits and amplifies the motion, resulting in a separation of the α and β legs and integrin extension [22]. On the other hand, the swing-out movement of the upper β leg could readily occur if it were preceded by extension of both legs.

Several models have been proposed to integrate the structural changes of integrins and consequent biochemical findings [33]. For example, a “switchblade” model proposed that the head structure with the large (~ 80°) Hybrid swing-out represents the high affinity state of βA. To provide the necessary space for the Hybrid swing-out, the model suggests that the integrin first fully extend its knees, converting the bent into a linear asymmetric conformation, described as such in 2D EM images [19]. An alternate “deadbolt” model suggest that elastic deformation of the F/α7 loop is possible with only modest quaternary changes at the βTD interface with βA and possibly Hybrid domains [34]. It has been found that upon binding of ICAM-5 to the LFA-1 I-domain, a remarkable outward movement of the α7 helix was observed, which resulted in the replacement of the corresponding α7 helix from a neighboring I-domain into the α7 helix position, but in an upside-down configuration. This α7 helix replacement was further propagated, resulting in a large I-domain/ICAM-5 cluster. In this way, a weak initial interaction between the integrin and a ligand can result in the formation of large ligand/receptor aggregates [35].

3. INTEGRIN SIGNALING

Integrins bind ECM proteins through their large extracellular domain, and engage the cytoskeleton via their short cytoplasmic tails. These integrin-mediated linkages on either side of the plasma membrane are dynamically linked. The cytoskeleton controls affinity and avidity of the integrin extracellular domain to modulate the ECM, and integrin binding to ECM changes the shape and composition of the cytoskeleton beneath [36]. Thus, integrins communicate over the plasma membrane in both directions, i.e., outside-in and inside-out signaling [18]. In outside-in signaling through integrins, ligands bind to extracellular integrin domains, where a conformational change occurs so that the signal is transmitted into the cell. Integrin clustering may also occur. Inside-out signaling originates from non-integrin cell surface receptors or cytoplasmic molecules and it activates signaling pathways inside the cells, ultimately resulting in the activation/deactivation of integrins. In this case, adhesion may be regulated both by conformational changes in the integrin and by valency change (integrin clustering). In fact, both signaling events may occur simultaneously and reinforce each other [8].

Changes in interactions and/or in the structures of the cytoplasmic domains of integrins within the membrane-proximal regions play crucial roles in integrin activation via inside-out signaling [37-38]. Conformational changes of integrin induced by ligand binding on the extracellular domain altered the cytoplasmic domain structures to elicit various intracellular signaling pathways. A prominent biochemical event in integrin outside-in signaling is protein tyrosine phosphorylation due to activation of Src and FAK family protein tyrosine kinases [39-40]. Src and its inhibitory Csk are constitutively bound to the integrin β-tails. Integrin binding to ligand induces Src activation through Csk dissociation, Src transphosphorylation and/or recruitment of tyrosine phosphatases (e.g receptor tyrosine phosphatase RPTPα, or PTP-1B [39]. However, the spatiotemporal and structural basis of the interaction of integrin cytoplasmic-tails with the growing list of signaling molecules including cytosolic and receptor kinases (Src, FAK, Syk, ILK and PKC) and phosphatases remains to be determined [9].

The integrin cytoplasmic domains play a central role in integrin activation [41-42]. However, the short integrin cytoplasmic tails lack enzymatic activity, and so depend on recruitment of adaptor molecules and signaling proteins for effector functions [36]. Talin is a major cytoskeletal protein that co-localizes with and binds to integrins and to actin and actin-binding proteins such as vinculin [43]. It has been demonstrated that binding of talin to the β cytoplasmic domain is a crucial, final step in activation of several classes of integrins [44-45]. Knockdown of talin expression in CHO (Chinese-hamster ovary) cells inhibits the activation of both β1 and β3 integrins without altering integrin expression [44]. NMR studies suggest that direct disruption of α-β tail interaction by the talin head domain result in integrin activation [46]. Proposed a two-step activation model, the talin head domain first recognizes the high-affinity binding site in the membrane-distal region, which provides a strong linkage between the talin and the integrin β tail, and subsequently binds to a second lower-affinity membrane proximal site that is involved in α-β association, triggering separation of the tails and integrin activation [47-48]. Although talin is an important player in integrin activation mechanisms, the possibility remains that other integrin tail-binding proteins can substitute for talin. For example, many other PTB-domain-containing proteins including Numb, Dok-1, ICAP-lα (integrin cytoplasmic domainassociated protein-lα) and Kindlins bind to integrin β tails in a similar fashion to talin [49].

Integrin activation requires transmission of conformational rearrangements from the cytoplasmic face to the extracellular domain. The interaction between the membrane-proximal regions of the α and β subunits is believed to be stabilized by a salt bridge between a conserved arginine residue in the α tail and an aspartate residue in the β tail and by the hydrophobic residues immediately N-terminal to the arginine and aspartate residues [50]. Mutations that disrupt this 'clasp' lead to integrin activation, and integrins can be constitutively activated by deletion or mutations in these membrane-proximal sequences [42]. These data together strongly indicate that this membrane-proximal interaction plays an essential role as a stabilizer in the association of the α and β membrane proximal regions, maintaining the integrins in a low-affinity state. In addition, mutational analysis and computational modeling together suggest that a helical interface between the integrin α and β subunit transmembrane domains stabilizes the inactive state, and suggest that disruption of this helical transmembrane interface leads to activation [51] [52].

4. LIGANGDS OF INTEGRINS

The majority of integrin ligands are protein components of ECM (Table 1). ECM is assembled from components synthesized and deposited outside the cell surface that provide structural and functional integrity to connective tissues and organs [53]. The ECM can also serve as a reservoir or provisional matrix for growth factors and plasma proteins found in the blood [54]. The protein components of ECM can be divided into three major classes: (1) structural proteins such as the collagens and elastin (although collagen can also have functional properties); (2) multidomain adhesive glycoproteins such as fibronectin, vitronectin, and laminin; and (3) matricellular proteins such as secreted protein acidic and rich in cysteine (SPARC; also known as osteonectin and BM-40), thrombospondin 1 (TSP1) and 2 (TSP2), tenascin C and X, and osteopontin [53]. Among them, collagen primarily provides tensile strength to the tissue and elastin is responsible for the elastic recoil. Fibronectin, an adhesive glycoprotein, is a multifunctional protein that can act as a structural molecule owing to its fibrillar architecture, a biological glue that mediates interactions between cells and other ECM proteins, or a bridge forming cell to cell contacts [55]. Matricellular proteins are secreted macromolecules that interact with cell-surface receptors, ECM, growth factors, and proteases but do not function as structural molecules per se [56]. These glycoproteins regulate interactions between cells and ECM. For instance, SPARC, TSP1, and tenascin C disrupt cell-matrix interactions (i.e., are counteradhesive) — a critical component of angiogenesis and tissue remodeling [57].

All five αV integrins, two β1 integrins (α5, α8) and αIIbβ3 share the ability to recognize ligands containing an RGD tripeptide active site, which is shared by The RGD binding integrins are among the most promiscuous in the family, with β3 integrins in particular binding to a large number of ECM and soluble vascular ligands including fibronectin, fibrinogen, vitronectin, vWF, LAP-TGFβ and Del-1. Although many ligands are shared by this subset of integrins, the rank order of ligand affinity varies, presumably reflecting the preciseness of the fit of the ligand RGD conformation with the specific α-β active site pockets [58].

Collagens are a major family of structural ECM proteins and characterized by the presence of triple helical regions. Cells employ four different αI domain containing integrins including α1, α2, α10, and α11 to maintain holds with them. Immunoglobulin superfamily members also act as ligands for several integrins, and the best characterized integrin ligands are VCAM-1 (Vascular Cell Adhesion Molecule) and the ICAMs. VCAM-1 binds to α4β1, αVβ3 and α4β7, whereas the leukocyte-specific CD11/CD18 integrins (including LFA-1 and Mac-1) bind to ICAMs [59].

 Table 1 

Ligands and distribution of integrins

Theranostics Image (Click on the image to enlarge.)

5. BIOLOGICAL AND PATHOLOGICAL FUNCTION OF INTEGRINS

Cell adhesion is involved in many essential normal cellular and pathological functions including cell survival, growth, differentiation, migration, inflammatory responses, platelet aggregation, tissue repair and tumor invasion. Integrins are one of key family proteins for cell adhesion regulation through binding to a large number of extracellular matrix molecules and cell membrane proteins. Using knockout mice it has become evident that the integrins possess both redundant and nonredundant functions, and that lack of expression may result in a wide variety of effects ranging from blockage in pre-implantation to embryonic orperinatal lethality and developmental defects.

β1 Integrin. The largest subgroup of integrins is formed by the β1 subunit containing integrins which consist of 12 members with different ligand binding properties. Besides ECM proteins, some β1 integrin containing receptors also interact with cellular receptors. For example, α4β1 and α9β1 bind to VCAM-1 and α4β1 to MadCAM-1 [60]. During early embryogenesis totipotent embryonic cells differentiate and polarize to form endoderm, basement membrane (BM), and ectoderm. However, embryoid bodies derived from β1-deficient ES cells develop endoderm, but do not form a BM, polarized ectoderm and a cavity [61]. β1-integrin null embryos die by embyronic day (E)9.5-10.5 in utero owing to implantation defects [62-63]. The major function of β1 integrin during early development may be to induce laminin-1 expression since exogenous addition of laminin 1 allows BM formation also in the absence of β1 integrins, though the signaling pathway mediating the regulation is still unclear [64]. β1 integrins are crucial for the attachment of basal keratinocytes to the BM, since loss of β1 leads to widespread blisters between the epidermis and the BM. In addition, loss of β1 integrin in skin decreases the proliferation of basal keratinocytes by about 70% [65]. Similarly to skin, β1 integrins are important for the attachment to and maintenance of the BM in brain [66]. Although β1 integrins are important ECM receptors, they are not generally required for cell migration. While some cells, such as keratinoctes or primordial germ cells, are highly dependent on β1 integrin, other such as myoblasts, neurons and lymphocytes migrate normally also in the absence of β1 integrin. Tumor cells expressing β1 integrin formed significantly larger primary tumors and had a dramatically increased metastasis into liver and lung [67]. Moreover, ablation of the β1 integrin gene in mammary epithelium dramatically impairs mammary tumorigenesis in mice [68]. However, in human patients, no clear correlation between tumor formation, invasion and β1 integrin expression could be identified yet.

Integrins α1β1 and α2β1 are expressed on lymphatic endothelium in healing wounds in response to VEGF. Inhibition of these integrins blocked lymphangiogenesis in these wounds [69]. In normal animals, VEGFA treatment upregulates expression of both α1β1 and α2β1 on vascular endothelial cells. Function-blocking antibodies directed against both integrins reduced VEGFA-induced angiogenesis in vivo and reduced tumor growth and angiogenesis [70]. Tumors grown in α1β1-deficient mice grew more slowly and exhibited less angiogenesis, indicating an important role for this integrin in angiogenesis [71]. However, mice lacking α2β1 integrins exhibit increased B16F10 melanoma growth and angiogenesis when compared with wild-type mice [72]. By contrast, Lewis lung carcinoma (LLC) tumors did not exhibit increased angiogenesis or growth in α2-null mice. The different response resulted from different level of a VEGFR1 binding placental growth factor (PLGF) expression which was high from B16F10 melanoma cells and low from LLC cells. Enhanced angiogenesis was attributed to an increase in VEGFR1 expression and function on α2-null endothelial cells [72].

Integrin α4β1, a receptor for VCAM and fibronectin containing the CS1 region, is best known as a lymphocyte integrin involved in adhesion and extravasation of lymphocytes by binding to VCAM1 which is expressed on inflamed endothelial cells. Loss of integrin α4 during development leads to defects in placentation, heart development and coronary artery development, causing lethality between E10.0 and E12.0 [73]. It has been reported that integrin α4β1 was expressed on neo-vasculatures in both murine and human tumors and responded to VEGF, bFGF, IL1 and TNF. Antagonists of α4β1 blocked tumor neovascularization by induction of cell death of both endothelial cells and pericytes and decreased tumor growth in chick and murine models of tumor growth [74]. It has been proposed that integrin α4β1-VCAM1 interactions facilitated close proximity of the endothelial cells and pericytes, which promoted the survival of both endothelial cells and pericytes during angiogenesis [74]. Moreover, integrin α4β1 selectively promotes the homing of both endothelial progenitor cells and monocytes to neovascular tissue [75]. Treatment of mice bearing LLC tumors with antagonists of integrin α4β1 significantly suppressed the number of monocytes and progenitor cells found within tumors and reduced blood vessel density [76], indicating that the suppression of monocyte and progenitor cell homing to tumors by integrin α4β1 antagonists could be a useful supplementary approach to suppress tumor angiogenesis and growth.

Embryonic deletion of the integrin α5 subunit induces early mesenchymal abnormalities, leading to lethality of α5-null embryos [77]. Further studies using α5-null ES cells to grow teratocarcinomas showed decreased proliferation, increased apoptosis and decreased vascularization in teratocarcinomas derived from α5-null ES cells compared with controls [78]. Integrin α5β1 expression is induced in response to a variety of angiogenic stimuli, such as bFGF, IL8 and the ECM protein DEL1 (also known as EDIL3), but not by VEGF [79]. Integrin α5β1-mediated adhesion promotes endothelial cell migration and survival in vivo and in vitro by suppressing the activity of protein kinase A (PKA) [80]. Integrin α5β1 is poorly expressed on quiescent endothelium but its expression is significantly upregulated on endothelium during tumor angiogenesis in both mice and humans [81]. In some types of cancer, integrin α5β1 is also expressed on tumor cells and plays a direct role in tumor cell migration, invasion, and survival [82-84]. A small peptide antagonist (amino-acid sequence PHSCN) to integrin α5β1 significantly reduced neovascularization and formation of metastases in an animal model of prostate carcinoma that expresses integrin α5β1 [83, 85-86]. Expression of α5β1 is also upregulated during corneal angiogenesis [87].

Integrin α6β1 is expressed at high levels in capillary endothelial cells in vivo [88]. Unlike α6β4, which shows a preference for laminin 5, integrin α6β1 binds most laminin isoforms as well as other ECM proteins including CYR61, thrombospondin 1 and thrombospondin 2 [89]. As α6 integrin antagonists and α6 small interfering RNA constructs inhibit angiogenesis, it is possible that integrin α6β1 promotes angiogenesis. However, as these agents can block the function of both integrins α6β1 and α6β4, it is not yet clear what part integrin α6β1 plays in tumor angiogenesis [88]. Antibody inhibitors of α6 integrin prevented endothelial cell tube formation in vitro, suggesting a role for α6 in the angiogenic process [88].

Integrin α9β1 is structurally similar to integrin α4β1. However, unlike α4β1, it is a receptor for a number of ECM proteins and cell surface receptors including tenascin C, thrombospondin, osteopontin, IIICS fibronectin, VCAM1 and other ligands [90]. Integrin α9β1 is expressed on epithelia, osteoclasts, smooth muscle cells and also endothelial cells. α9β1 promotes VEGFA-stimulated angiogenesis by directly binding to VEGFA and blocking antibodies to α9β1 suppress VEGFA-induced angiogenesis [91]. However, other studies found that α9β1 also binds directly to the N terminus of thrombospondin and blocking antibodies to α9β1 inhibited angiogenesis induced by this thrombospondin fragment [92]. Integrin α9β1 also has a role in growth factor-mediated lymphangiogenesis as PROX1, a lymphatic endothelial cell-selective transcription factor, coordinately upregulates integrin α9β1 and VEGFR3 expression and endothelial cell motility in vivo [93]. This integrin promotes VEGFC- and VEGFD-stimulated cell migration by directly binding these growth factors and antagonism of α9β1 suppresses VEGFC-induced motility [94]. Taken together, these studies indicate that α9β1 has unique and crucial roles in lymphangiogenesis. Indeed, integrin α9β1-null mice die 8-12 days after birth owing to lethal defects in development of the lymphatic system; however, they do not exhibit obvious defects in development of blood vessels [95].

αvβ3 Integrin. The integrin αvβ3 is the first of the αv integrins to be characterized and shown to regulate angiogenesis [96-97]. It binds with multiple components of the ECM including vitronectin, fibronectin, fibrinogen and osteopontin since they are all RGD-containing proteins. It has been found in 1994 that integrin αvβ3 was widely expressed on blood vessels in human tumor biopsy samples but not on vessels in normal human tissues. Its expression on endothelial cells is stimulated by angiogenic growth factors such as bFGF, TNFα and IL8 and it is upregulated on endothelium in tumors, wounds and sites of inflammation αvβ3 integrin has a key role in endothelial cell survival and migration during angiogenesis [96] [98]. Antagonists of αvβ3 inhibited angiogenesis and tumor growth in a variety of animal models of cancer and blocked corneal as well as choroidal angiogenesis in animal models of ocular disease [98-99]. In addition, integrin αvβ3 antagonists induce endothelial cell apoptosis through a caspase 8-dependent cell death program [100]. In vitro studies revealed that agonists of endothelial cell αvβ3, but not other integrins, suppressed p53 activity, blocked p21WAF1/CIP1 expression, and increased the bcl-2/bax ratio, thereby promoting cell survival [101]. Ligation of endothelial αvβ3 integrin has also been shown to activate mitogen-activated protein kinase (MAPK), FAK and Src, among other kinases, resulting in cell proliferation, differentiation and migration [102].

Based on the sizable body of evidence addressed above, it is reasonable to draw the conclusion that integrin αvβ3 promotes angiogenesis and endothelial cell survival and that antagonism of this integrin suppresses angiogenesis by inducing endothelial cell apoptosis in vitro and in vivo. Indeed, antagonists of β3 integrin are being used in clinical trials as anti-angiogenic therapy, including the humanized monoclonal antibody Vitaxin and the RGD mimetic Cilengitide [103-104]. However, these agents did not appear to be as successful at inhibiting angiogenesis in clinical trials for cancer treatment as originally hoped [105]. Recently, it has been reported that low concentrations of RGD-mimetic integrin inhibitors promote VEGF mediated angiogenesis by altering αvβ3 integrin and vascular endothelial growth factor receptor-2 trafficking, thereby stimulating tumor growth and angiogenesis [106].

More importantly, a series of genetically Knock-out studies forced researchers to reconsider the role of integrin αvβ3 and αvβ5 in angiogenesis. For example, genetic ablation of the αv integrin subunit did not appear to affect developmental angiogenesis [107]. Even conditional deletion of αv integrin in Tie2-expressing endothelial cells is not sufficient to affect angiogenesis either [108]. Furthermore, β3 null and β3/β5 doubly deficient mice produce vascular networks without obvious defects during developmental angiogenesis, and more surprisingly, display enhanced tumor growth and pathological angiogenesis [109-110]. However, male mice lacking β3 integrin exhibit coronary capillaries of irregular endothelial thickness, with endothelial protrusions into the lumen, and expanded cytoplasmic vacuoles. These defective coronary vessels can be normalized by administration of inhibitors of VEGF or VEGF receptor 2 (VEGFR2, also known as KDR), suggesting that enhanced VEGF signaling might compensate for the loss of β3 integrin [111]. In addition, with a mouse knockin model, it has been demonstrated that the phosphorylation of Tyr747 and Tyr459 in β3 integrin participates in enhancing pathological angiogenesis [112].

All considered, the above studies suggest that avβ3 integrin may have both positive and negative roles during angiogenesis. Indeed, avβ3 can bind a plethora of factors that are thought to enhance angiogenesis including VEGFR2, vitronectin, fibronectin, Del1, ANGPTL3, CYR61, bone sialoprotein, thrombin, and can also bind to several factors that are thought to induce anti-angiogenic effects including thrombosondin, angiostatin, and tumstatin [113]. Another explanation is that functioning as a biosensor, avβ3 may promote angiogenesis in the ligated state, but when ligands are absent or ligand binding is antagonized, avβ3 may activate a death pathway to inhibit angiogenesis. Thus, depending on the microenvironment and the ligation state, integrins promote or inhibit angiogenesis by positively or negatively regulating cell survival [114]. In this way, integrin avβ3 appears to function as a regulator of angiogenesis by balancing opposing signals in the tumor microenvironment.

αvβ5 integrin. All though integrin αvβ5 binds with similar ECM components with αvβ3, the related angiogenic promoting pathway is distinct from that regulated by αvβ3. For example, anti-αvβ3 antibodies blocked angiogenesis induced by bFGF, whereas antibodies that target αvβ5 blocked the angiogenesis induced by VEGF in both the rabbit corneal eye pocket and the chick chorioallantoic membrane assay [115]. The VEGF- αvβ5 pathway is dependent on Src kinase and protein kinase C30. In vivo angiogenesis assays showed αvβ5 is required for TGF- β and VEGF-mediated angiogenesis and VEGF acted through αvβ5 to promote vascular permeability [116], indicating αvβ5 may also promote tumor metastasis [117]. However, integrin αvβ5-null mice exhibit completely normal development and normal angiogenesis [118], indicating that this integrin is not required for vascular development.

Genetic ablations of the αv subunit, which eliminate expression of integrins αvβ1, αvβ3, αvβ5, αvβ6 and αvβ8 suggest that, in some mice, αv integrins are not required for blood vessel development in most tissues. Twenty percent of embryos lacking αv integrins survive to birth with normal blood vessels in many tissues. However, 80% of mice die in utero between E10.5 and E11.5 with defective placental blood vessels. The remaining 20% of αv-null mice die shortly after birth with severe brain and intestinal haemorrhage, with distended and leaky vessels in these tissues [107]. Thus, αv integrins appear to have key roles in embryonic development of blood vessels in tissues such as placenta and brain.

αvβ6 integrin. The αvβ6 receptor is the only known integrin that is restricted exclusively to epithelial cells [119]. The αvβ6 integrin is expressed primarily during embryonic development and is not expressed constitutively in healthy epithelia. However, αvβ6 is upregulated during tissue remodeling, including wound healing and carcinogenesis [120]. αvβ6 facilitates keratinocyte adhesion and migration on fibronectin, tenascin and vitronectin, all of which are components of the early wound matrix [121]. Using mouse β6-/- keratinocytes, Huang et al. found that αvβ6 expression promotes keratinocyte migration through a pathway involvling protein kinase C [122]. Binding of αvβ6 to its ligand upregulated secretion of the pro-enzyme form of type IV collagenase, MMP-9, and exogenous activation of MMP-9 further increased keratinocyte migration [123]. Thomas et al. demonstrated that binding of αvβ6 to the TGFb1 latency associated peptide (LAP) promotes cell migration and MMP-9 expression, and also that cells will invade towards soluble LAP in an αvβ6-dependent manner [124]. In addition, TGFb1 induces de novo expression of αvβ6 in normal human keratinocytes [125] and on the non-transformed keratinocyte cell line, HaCaT [126].

To date, αvβ6 expression has been reported in carcinomas of the lung, breast, pancreas, stomach, colon, ovary, salivary gland as well as oral and skin squamous cell carcinoma [120, 127-131]. Elevated αvβ6 expression facilitated the invasion and dissemination of colon carcinoma cells in vivo [132-133]. The β6 overexpressing cell line was significantly more invasive, which was, in part, through αvβ6-dependent upregulation of the type IV collagenase MMP-9 [134-135]. High αvβ6 expression correlated with elevated uPA, uPAR and MMP-9 in ovarian carcinoma cell lines [136]. It has also been proposed that contribution of αvβ6 for promoting cancer progression in vivo is related to the mechanism of epithelial-mesenchymal transition (EMT) by activating latent TGF-b [137]. The upregulation of αvβ6 related with the poor prognosis [132], suggesting that αvβ6 expression may be useful in predicting malignant transformation. Indeed, the integrin αvβ6 now emerges as an attractive new candidate as a therapeutic target for metastatic colon carcinoma. However, epithelial cells in samples of lichen planus (a chronic mucocutaneous disease) have also been shown to express αvβ6 suggesting that αvβ6 expression per se is insufficient to drive malignant progression [138]. The net effect on tumor behavior is likely to depend on the stage of tumor development. In the later stages of tumor development, as cells become refractory to growth inhibition, then the role of LAP in promoting both αvβ6-dependent cell movement and MMP-9 expression may become prominent, culminating in a pro-oncogenic effect of TGFb [139].

α6β4 Integrin. α6β4 plays a key role in the formation and stabilization of junctional adhesion complexes called hemidesmosomes (HDs) that are connected to the intermediate filament (IF) system, as well as in the regulation of a variety of signaling processes. Increased expression of α6β4 and changes in its distribution were then correlated with increased aggressiveness of tumors and poor prognosis [140]. β4 subunit has an unusual size of approximately 200 kDa, which is due to an unusually long cytoplasmic domain of over 1,000 amino acids [141]. This domain contains two pairs of type III fibronectin (FNIII) domains, separated by a connecting segment (CS) [142]. β4 knockout mice developed severe blistering of the skin [143]. Moreover, a mutation in the β4 gene is responsible for the pyloric atresia associated with junctional epidermolysis bullosa (EB) syndrome in humans. It has been found that interaction between α6β4 and plectin is critical for proper HD assembly and at least two sites on plectin and three on β4 mediate their interaction. The actin binding domain (ABD) of plectin binds to the first pair of FNIII domains and part of the CS of β4 [144]. Two other HD components, BP180 and BP230, bind to the third FNIII domain of β4 and to a region comprising the C-terminal end of the CS and the second pair of FNIII domains, respectively [145]. The α6 subunit of α6β4 interacts with the tetraspanin CD151 [146].

Apart from promoting keratinocytes migration, studies on the invasion of carcinoma cells revealed a role for α6β4-dependent activation of phosphatidylinositol (PI)-3 kinase, which is an upstream regulator of Rac1 [147]. Since growth factors activate enzymes that initiate the disassembly of HDs, the presence of overactive growth factor receptors may explain why α6β4 is unable to initiate HD formation in many carcinoma cells. In fact, α6β4 cooperates with several different tyrosine kinases in carcinoma cells to promote invasion, including c-met (hepatocyte growth factor receptor), ErbB2 and ErbB1 [148]. There is evidence that proteins other than tyrosine kinases can cooperate with α6β4 to promote invasion. For example, invasion of breast carcinoma cells is stimulated by promoting Rab11-mediated vesicular trafficking under hypoxic conditions [149].

Leukocytes specific integrins. The arrest of leukocytes rolling on target vascular beds involves rapid formation of shear-resistant adhesions by specialized leukocyte integrins. This arrest can be mediated by integrins that contain the β2 subunit, e.g. aLβ2 (leukocyte functionassociated antigen-1 (LFA-1)) or α4 subunit, e.g. α4β1 (very late antigen-4 (VLA-4)). In leukocytes, integrins are involved in slow rolling, adhesion strengthening, and transendothelial migration [150-151]. Lymphocyte and myeloid cells cease rolling and arrest on lymph node high endothelial venules as well as on peripheral tissues upon activation of at least one of the four major leukocyte integrins: VLA-4, α4β7, LFA-1, and the myeloidspecific integrin (integrin αMβ2 (Mac-1)) [152]. In addition, these integrins transmit signals that facilitate respiratory burst, complement-mediated phagocytosis, cytokine production, proliferation, survival, differentiation, degranulation, and cellular polarization. Loss or reduced β2 on cell surface, defects in β2 signaling, mutations in β2 will cause leukocyte adhesion deficiencies (LAD) [153].

Most circulating leukocytes maintain their integrins in largely low affinity state [154]. Leukocyte integrins must undergo in situ modulation to develop high avidity for their endothelial ligands to establish shear-resistant adhesion and firm leukocyte arrest on the target endothelial site [155]. For most leukocytes, this dramatic change in integrin affinity is triggered when the rolling leukocyte encounters and rapidly responds to a proper chemoattractant signal presented on the apical endothelial surface [156]. The distribution of LFA-1 integrins to the leading edge of a polarized leukocyte is reported to proceed through a signaling cascade involving Rap1 and its downstream effectors RAPL and the threonine-serine kinase, Mst1 [157]. Integrins play key roles in cellular migration acting both as adhesive molecules that maintain locomotion over the apical endothelial surface and as signaling molecules, which, together with chemokine signals, maintain polarity and motility [158].

Leukocyte integrins are recognized therapeutic targets in various diseases, and integrin blocking monoclonal antibodies (natalizumab against α4 integrins and efalizumab against LFA-1) are already used in the clinic against multiple sclerosis and psoriasis [159-160]. Leukocyte adhesion cannot be inhibited by compounds containing the RGD sequence, but longer peptides to recognition sites in ICAM molecules or microbe-derived ICAM-1 inhibitors do show inhibitory activity [161-162]. It has been reported that promatrix metalloproteinases (proMMPs), particularly proMMP-9, are potent ligands of the leukocyte β2 integrins and translocating proMMP-9/ αMβ2 complex is part of the cell surface machinery guiding neutrophil migration [163], suggesting that a promising therapeutic approach could be to disrupt the association between the matrix metalloproteases and integrins. It has also been found that the Del-1 protein is an important endogenous inhibitor of leukocyte adhesion [164]. The Del-1 protein is a secreted protein expressed by endothelial cells in immunoprivileged tissues, such as the brain, the eye, and the lung. Although a secreted molecule, Del-1 is absent from plasma and is rather localised to endothelial cells and/or the extracellular matrix [164]. In fact, it binds to the β2 integrins (LFA-1, Mac-1) and when coated on plastic, leukocytes adhere to the protein. However, leukocyte binding to ICAM-1 is inhibited when both Del-1 and ICAM-1 are present. Del-1 knockout mice show a strong activation of adhesion and of inflammatory cell recruitment [164].

6. PERSPECTIVES OF INTEGRINS AS IMAGING AND THERAPY TARGETS

Integrins are ideal pharmacological targets based on both the key role they played in angiogenesis, leukocytes function and tumor development and easy accessibility as cell surface receptors interacting with extracellular ligands [1]. So far, the integrin superfamily represents the best opportunity of targeting both antibodies and small-molecule antagonists for both therapeutic and diagnostic utility in various key diseases [165]. Preclinical studies and clinical trials showed that quite a few integrin targeting antibodies were effective to block tumor growth and metastasis. Most of studies focused on αv integrins including MEDI-522 (vitaxin) against αvβ3 [98], CNTO 95 against both αvβ3 and αvβ5 [166], 17E6 against αvβ3, αvβ5 and αvβ1 [167]. Besides, antibodies targeting to other integrins have been developed. For example, Tysabri (natalizumab), an antibody which blocks α4 integrins and inhibits the α4-mediated adhesion of leukocytes to their counter receptor was used for treatment of patients with relapsing forms of multiple sclerosis (MS) [168]. Small molecular antagonists, mainly based on RGD containing peptides and RGD peptidomimetic [169-171], also showed potent inhibition of angiogenesis. More detailed information can be found in several recently published review articles [1, 172].

Integrin ligands are also under investigation as tumor endothelium-targeted diagnostic agents and integrin targeting is proving useful in tumor imaging. Both peptide and antibody-based diagnostic agents targeting RGD-binding integrins or αv integrins have been evaluated in animal models of cancer after 18F or 64Cu labeling. Tumor xenografts with positive integrin αvβ3 expression were visualized clearly on PET images [173-175]. Other imaging modalities besides PET have also been investigated for integrin αvβ3 targeted imaging. For example, integrin αv-targeted ultrasound microbubbles preferentially bound neovasculature at the periphery of experimental tumors [176]. The clinical significance of molecular imaging with integrin-targeting agents may be useful for lesion detection and grading. In addition, imaging will help identify appropriate patients for integrins related therapy and monitor the therapeutic responses. More important, integrin-targeting agents might also be useful in selectively delivering chemotherapeutics or gene therapeutic agents to tumors, thus minimizing systemic toxicities. For example, after fused with a RGD targeting moiety, RGD4C-TNF showed improved tumor accumulation and therapy effect in a human breast tumor model [177].

With regard to activity, signaling and regulation of integrins, evidences are accumulating with more crystal structures deciphered and new models established. However, the integrin pathways are still not fully understood due to extreme complexity. Besides their ligands, increasing number of biomolecules has been identified interacting with integrins including VEGF/VEGFR [178], HER2 [179], MMPs [180], uPAR [181]. Moreover, it has been found that ligand-bound integrins also actively suppress the activation of other integrins in the same cell utilizing different signaling pathways. For example, when α2β1 is ligated, both α5β1 and αVβ3 will be suppressed through PKA. When α5β1 is ligated, α2β1 will be suppressed through PKCα [182]. Integrins are also known to have transdominant roles over other integrins and can thus control overall cell behavior [183]. After epithelial integrity is restored in wounds, αvβ6 expression will be strong upregulated. However, mutating the β6 cytoplasmic domain by removing the terminal 11 amino acids prevents this density-dependent upregulation of αvβ6 and replaces it by upregulating αvβ5. This provides evidence that the expression of these integrins is linked and expression may be switched from one to the other [135].

So far, a lot of breakthroughs in integrin research have been made with purified integrins, or I-domains and their ligands. However, it is becoming increasingly apparent that integrin mediated cell adhesion is unusually complex. Thus, it is critical to study the events occurring at the cellular and organism levels in a temporal manner to make more meaningful conclusions. It is very promising for molecular imaging of living cells or animal models to meet the requirement. For example, microscopic imaging with FRET could identify integrin-integrin interaction and integrin-other proteins interaction in living cells [184] [185]. PET imaging with positron emission radioisotopes labeled integrin-targeting probes could visualize expression and regulation of integrins in animal models in a real-time mode [186]. We believe integrating data from both microscopic and macroscopic methods will quicken our steps on the long scientific journey to decipher the integrins related pathways.

Acknowledgements

This work was supported by the intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH). Dr. G. Niu currently is an Imaging Sciences Training Fellowship jointly supported by the Radiology and Imaging Sciences Department, NIH Clinical Center and the Intramural Research Program, NIBIB, NIH.

CONFLICT OF INTEREST

The authors have declared that no conflict of interest exists.

References

1. Lu X, Lu D, Scully M, Kakkar V. The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy. Perspect Medicin Chem. 2008;2:57-73

2. Hynes RO. Integrins: a family of cell surface receptors. Cell. 1987;48:549-54

3. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11-25

4. Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp Cell Res. 2006;312:651-8

5. Brakebusch C, Bouvard D, Stanchi F, Sakai T, Fassler R. Integrins in invasive growth. J Clin Invest. 2002;109:999-1006

6. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673-87

7. Vogel V, Sheetz M. Local force and geometry sensing regulate cell functions. Nat Rev Mol Cell Biol. 2006;7:265-75

8. Ginsberg MH, Partridge A, Shattil SJ. Integrin regulation. Curr Opin Cell Biol. 2005;17:509-16

9. Springer TA. Complement and the multifaceted functions of VWA and integrin I domains. Structure. 2006;14:1611-6

10. Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL. et al. Crystal structure of the extracellular segment of integrin αVβ3. Science. 2001;294:339-45

11. Gahmberg CG, Fagerholm SC, Nurmi SM, Chavakis T, Marchesan S, Gronholm M. Regulation of integrin activity and signalling. Biochim Biophys Acta. 2009;1790:431-44

12. Takagi J. Structural basis for ligand recognition by integrins. Curr Opin Cell Biol. 2007;19:557-64

13. Lee JO, Bankston LA, Arnaout MA, Liddington RC. Two conformations of the integrin A-domain (I-domain): a pathway for activation?. Structure. 1995;3:1333-40

14. Lee JO, Rieu P, Arnaout MA, Liddington R. Crystal structure of the A domain from the α subunit of integrin CR3 (CD11b/CD18). Cell. 1995;80:631-8

15. Shimaoka M, Xiao T, Liu JH, Yang Y, Dong Y, Jun CD. et al. Structures of the αL I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell. 2003;112:99-111

16. Emsley J, Knight CG, Farndale RW, Barnes MJ, Liddington RC. Structural basis of collagen recognition by integrin α2β1. Cell. 2000;101:47-56

17. Song G, Yang Y, Liu JH, Casasnovas JM, Shimaoka M, Springer TA. et al. An atomic resolution view of ICAM recognition in a complex between the binding domains of ICAM-3 and integrin αLβ2. Proc Natl Acad Sci U S A. 2005;102:3366-71

18. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol. 2007;25:619-47

19. Nishida N, Xie C, Shimaoka M, Cheng Y, Walz T, Springer TA. Activation of leukocyte β2 integrins by conversion from bent to extended conformations. Immunity. 2006;25:583-94

20. Takagi J, Strokovich K, Springer TA, Walz T. Structure of integrin α5β1 in complex with fibronectin. EMBO J. 2003;22:4607-15

21. Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL. et al. Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand. Science. 2002;296:151-5

22. Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature. 2004;432:59-67

23. Curnis F, Longhi R, Crippa L, Cattaneo A, Dondossola E, Bachi A. et al. Spontaneous formation of L-isoaspartate and gain of function in fibronectin. J Biol Chem. 2006;281:36466-76

24. Takahashi S, Leiss M, Moser M, Ohashi T, Kitao T, Heckmann D. et al. The RGD motif in fibronectin is essential for development but dispensable for fibril assembly. J Cell Biol. 2007;178:167-78

25. DiCara D, Rapisarda C, Sutcliffe JL, Violette SM, Weinreb PH, Hart IR. et al. Structure-function analysis of Arg-Gly-Asp helix motifs in αvβ6 integrin ligands. J Biol Chem. 2007;282:9657-65

26. Shiu JH, Chen CY, Chang LS, Chen YC, Lo YH, Liu YC. et al. Solution structure of gamma-bungarotoxin: the functional significance of amino acid residues flanking the RGD motif in integrin binding. Proteins. 2004;57:839-49

27. Pasterkamp RJ, Peschon JJ, Spriggs MK, Kolodkin AL. Semaphorin 7A promotes axon outgrowth through integrins and MAPKs. Nature. 2003;424:398-405

28. Suzuki K, Okuno T, Yamamoto M, Pasterkamp RJ, Takegahara N, Takamatsu H. et al. Semaphorin 7A initiates T-cell-mediated inflammatory responses through α1β1 integrin. Nature. 2007;446:680-4

29. Aumailley M, Bruckner-Tuderman L, Carter WG, Deutzmann R, Edgar D, Ekblom P. et al. A simplified laminin nomenclature. Matrix Biol. 2005;24:326-32

30. Nishiuchi R, Takagi J, Hayashi M, Ido H, Yagi Y, Sanzen N. et al. Ligand-binding specificities of laminin-binding integrins: a comprehensive survey of laminin-integrin interactions using recombinant α3β1, α6β1, α7β1 and α6β4 integrins. Matrix Biol. 2006;25:189-97

31. Ido H, Harada K, Futaki S, Hayashi Y, Nishiuchi R, Natsuka Y. et al. Molecular dissection of the α-dystroglycan- and integrin-binding sites within the globular domain of human laminin-10. J Biol Chem. 2004;279:10946-54

32. Kunneken K, Pohlentz G, Schmidt-Hederich A, Odenthal U, Smyth N, Peter-Katalinic J. et al. Recombinant human laminin-5 domains. Effects of heterotrimerization, proteolytic processing, and N-glycosylation on α3β1 integrin binding. J Biol Chem. 2004;279:5184-93

33. Arnaout MA, Mahalingam B, Xiong JP. Integrin structure, allostery, and bidirectional signaling. Annu Rev Cell Dev Biol. 2005;21:381-410

34. Xiong JP, Stehle T, Goodman SL, Arnaout MA. New insights into the structural basis of integrin activation. Blood. 2003;102:1155-9

35. Zhang H, Casasnovas JM, Jin M, Liu JH, Gahmberg CG, Springer TA. et al. An unusual allosteric mobility of the C-terminal helix of a high-affinity αL integrin I domain variant bound to ICAM-5. Mol Cell. 2008;31:432-7

36. Geiger B, Bershadsky A, Pankov R, Yamada KM. Transmembrane crosstalk between the extracellular matrix--cytoskeleton crosstalk. Nat Rev Mol Cell Biol. 2001;2:793-805

37. Calderwood DA. Integrin activation. J Cell Sci. 2004;117:657-66

38. Hughes PE, O'Toole TE, Ylanne J, Shattil SJ, Ginsberg MH. The conserved membrane-proximal region of an integrin cytoplasmic domain specifies ligand binding affinity. J Biol Chem. 1995;270:12411-7

39. Arias-Salgado EG, Lizano S, Sarkar S, Brugge JS, Ginsberg MH, Shattil SJ. Src kinase activation by direct interaction with the integrin β cytoplasmic domain. Proc Natl Acad Sci U S A. 2003;100:13298-302

40. Cluzel C, Saltel F, Lussi J, Paulhe F, Imhof BA, Wehrle-Haller B. The mechanisms and dynamics of αvβ3 integrin clustering in living cells. J Cell Biol. 2005;171:383-92

41. Kim M, Carman CV, Springer TA. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science. 2003;301:1720-5

42. O'Toole TE, Mandelman D, Forsyth J, Shattil SJ, Plow EF, Ginsberg MH. Modulation of the affinity of integrin αIIbβ3 (GPIIb-IIIa) by the cytoplasmic domain of αIIb. Science. 1991;254:845-7

43. Calderwood DA, Zent R, Grant R, Rees DJ, Hynes RO, Ginsberg MH. The Talin head domain binds to integrin β subunit cytoplasmic tails and regulates integrin activation. J Biol Chem. 1999;274:28071-4

44. Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, de Pereda JM. et al. Talin binding to integrin β tails: a final common step in integrin activation. Science. 2003;302:103-6

45. Calderwood DA, Yan B, de Pereda JM, Alvarez BG, Fujioka Y, Liddington RC. et al. The phosphotyrosine binding-like domain of talin activates integrins. J Biol Chem. 2002;277:21749-58

46. Vinogradova O, Velyvis A, Velyviene A, Hu B, Haas T, Plow E. et al. A structural mechanism of integrin αIIbβ3 "inside-out" activation as regulated by its cytoplasmic face. Cell. 2002;110:587-97

47. Garcia-Alvarez B, de Pereda JM, Calderwood DA, Ulmer TS, Critchley D, Campbell ID. et al. Structural determinants of integrin recognition by talin. Mol Cell. 2003;11:49-58

48. Wegener KL, Partridge AW, Han J, Pickford AR, Liddington RC, Ginsberg MH. et al. Structural basis of integrin activation by talin. Cell. 2007;128:171-82

49. Calderwood DA, Fujioka Y, de Pereda JM, Garcia-Alvarez B, Nakamoto T, Margolis B. et al. Integrin β cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. Proc Natl Acad Sci U S A. 2003;100:2272-7

50. Ma YQ, Yang J, Pesho MM, Vinogradova O, Qin J, Plow EF. Regulation of integrin αIIbβ3 activation by distinct regions of its cytoplasmic tails. Biochemistry. 2006;45:6656-62

51. Stefansson A, Armulik A, Nilsson I, von Heijne G, Johansson S. Determination of N- and C-terminal borders of the transmembrane domain of integrin subunits. J Biol Chem. 2004;279:21200-5

52. Luo BH, Springer TA, Takagi J. A specific interface between integrin transmembrane helices and affinity for ligand. PLoS Biol. 2004;2:e153

53. Schultz GS, Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen. 2009;17:153-62

54. Macri L, Silverstein D, Clark RA. Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv Drug Deliv Rev. 2007;59:1366-81

55. Clark RA. Fibronectin matrix deposition and fibronectin receptor expression in healing and normal skin. J Invest Dermatol. 1990;94:128S-34S

56. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol. 1995;130:503-6

57. Sage EH. Regulation of interactions between cells and extracellular matrix: a command performance on several stages. J Clin Invest. 2001;107:781-3

58. Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J Cell Sci. 2006;119:3901-3

59. Rothlein R, Dustin ML, Marlin SD, Springer TA. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol. 1986;137:1270-4

60. Brakebusch C, Fassler R. β1 integrin function in vivo: adhesion, migration and more. Cancer Metastasis Rev. 2005;24:403-11

61. Aumailley M, Pesch M, Tunggal L, Gaill F, Fassler R. Altered synthesis of laminin 1 and absence of basement membrane component deposition in β1 integrin-deficient embryoid bodies. J Cell Sci. 2000;113(Pt 2):259-68

62. Fassler R, Meyer M. Consequences of lack of β1 integrin gene expression in mice. Genes Dev. 1995;9:1896-908

63. Stephens LE, Sutherland AE, Klimanskaya IV, Andrieux A, Meneses J, Pedersen RA. et al. Deletion of β1 integrins in mice results in inner cell mass failure and peri-implantation lethality. Genes Dev. 1995;9:1883-95

64. Li S, Harrison D, Carbonetto S, Fassler R, Smyth N, Edgar D. et al. Matrix assembly, regulation, and survival functions of laminin and its receptors in embryonic stem cell differentiation. J Cell Biol. 2002;157:1279-90

65. Brakebusch C, Grose R, Quondamatteo F, Ramirez A, Jorcano JL, Pirro A. et al. Skin and hair follicle integrity is crucially dependent on β1 integrin expression on keratinocytes. EMBO J. 2000;19:3990-4003

66. Graus-Porta D, Blaess S, Senften M, Littlewood-Evans A, Damsky C, Huang Z. et al. β1-class integrins regulate the development of laminae and folia in the cerebral and cerebellar cortex. Neuron. 2001;31:367-79

67. Brakebusch C, Wennerberg K, Krell HW, Weidle UH, Sallmyr A, Johansson S. et al. Β1 integrin promotes but is not essential for metastasis of ras-myc transformed fibroblasts. Oncogene. 1999;18:3852-61

68. White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U. et al. Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell. 2004;6:159-70

69. Hong YK, Lange-Asschenfeldt B, Velasco P, Hirakawa S, Kunstfeld R, Brown LF. et al. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the α1β1 and α2β1 integrins. FASEB J. 2004;18:1111-3

70. Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through α1β1 and α2β1 integrins. Proc Natl Acad Sci U S A. 1997;94:13612-7

71. Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA. Elevated matrix metalloprotease and angiostatin levels in integrin α 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A. 2000;97:2202-7

72. Zhang Z, Ramirez NE, Yankeelov TE, Li Z, Ford LE, Qi Y. et al. α2β1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner. Blood. 2008;111:1980-8

73. Yang JT, Rayburn H, Hynes RO. Cell adhesion events mediated by α4 integrins are essential in placental and cardiac development. Development. 1995;121:549-60

74. Garmy-Susini B, Jin H, Zhu Y, Sung RJ, Hwang R, Varner J. Integrin α4β1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. J Clin Invest. 2005;115:1542-51

75. Jin H, Aiyer A, Su J, Borgstrom P, Stupack D, Friedlander M. et al. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J Clin Invest. 2006;116:652-62

76. Jin H, Su J, Garmy-Susini B, Kleeman J, Varner J. Integrin α4β1 promotes monocyte trafficking and angiogenesis in tumors. Cancer Res. 2006;66:2146-52

77. Yang JT, Rayburn H, Hynes RO. Embryonic mesodermal defects in α5 integrin-deficient mice. Development. 1993;119:1093-105

78. Taverna D, Hynes RO. Reduced blood vessel formation and tumor growth in α5-integrin-negative teratocarcinomas and embryoid bodies. Cancer Res. 2001;61:5255-61

79. Boudreau NJ, Varner JA. The homeobox transcription factor Hox D3 promotes integrin α5β1 expression and function during angiogenesis. J Biol Chem. 2004;279:4862-8

80. Kim S, Harris M, Varner JA. Regulation of integrin αvβ3-mediated endothelial cell migration and angiogenesis by integrin α5β1 and protein kinase A. J Biol Chem. 2000;275:33920-8

81. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin. Am J Pathol. 2000;156:1345-62

82. Gong J, Wang D, Sun L, Zborowska E, Willson JK, Brattain MG. Role of α5β1 integrin in determining malignant properties of colon carcinoma cells. Cell Growth Differ. 1997;8:83-90

83. Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S. et al. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res. 2000;60:309-20

84. O'Brien V, Frisch SM, Juliano RL. Expression of the integrin α5 subunit in HT29 colon carcinoma cells suppresses apoptosis triggered by serum deprivation. Exp Cell Res. 1996;224:208-13

85. Umeda N, Kachi S, Akiyama H, Zahn G, Vossmeyer D, Stragies R. et al. Suppression and regression of choroidal neovascularization by systemic administration of an α5β1 integrin antagonist. Mol Pharmacol. 2006;69:1820-8

86. Dietrich T, Onderka J, Bock F, Kruse FE, Vossmeyer D, Stragies R. et al. Inhibition of inflammatory lymphangiogenesis by integrin α5 blockade. Am J Pathol. 2007;171:361-72

87. Muether PS, Dell S, Kociok N, Zahn G, Stragies R, Vossmeyer D. et al. The role of integrin α5β1 in the regulation of corneal neovascularization. Exp Eye Res. 2007;85:356-65

88. Lee TH, Seng S, Li H, Kennel SJ, Avraham HK, Avraham S. Integrin regulation by vascular endothelial growth factor in human brain microvascular endothelial cells: role of α6β1 integrin in angiogenesis. J Biol Chem. 2006;281:40450-60

89. Leu SJ, Liu Y, Chen N, Chen CC, Lam SC, Lau LF. Identification of a novel integrin α6β1 binding site in the angiogenic inducer CCN1 (CYR61). J Biol Chem. 2003;278:33801-8

90. Liao YF, Gotwals PJ, Koteliansky VE, Sheppard D, Van De Water L. The EIIIA segment of fibronectin is a ligand for integrins α9β1 and α4β1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J Biol Chem. 2002;277:14467-74

91. Vlahakis NE, Young BA, Atakilit A, Hawkridge AE, Issaka RB, Boudreau N. et al. Integrin α9β1 directly binds to vascular endothelial growth factor (VEGF)-A and contributes to VEGF-A-induced angiogenesis. J Biol Chem. 2007;282:15187-96

92. Staniszewska I, Zaveri S, Del Valle L, Oliva I, Rothman VL, Croul SE. et al. Interaction of α9β1 integrin with thrombospondin-1 promotes angiogenesis. Circ Res. 2007;100:1308-16

93. Mishima K, Watabe T, Saito A, Yoshimatsu Y, Imaizumi N, Masui S. et al. Prox1 induces lymphatic endothelial differentiation via integrin α9 and other signaling cascades. Mol Biol Cell. 2007;18:1421-9

94. Vlahakis NE, Young BA, Atakilit A, Sheppard D. The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin α9β1. J Biol Chem. 2005;280:4544-52

95. Huang XZ, Wu JF, Ferrando R, Lee JH, Wang YL, Farese RVJr. et al. Fatal bilateral chylothorax in mice lacking the integrin α9β1. Mol Cell Biol. 2000;20:5208-15

96. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science. 1994;264:569-71

97. Cheresh DA. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci U S A. 1987;84:6471-5

98. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G. et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-64

99. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S. et al. Involvement of integrins αvβ3 and αvβ5 in ocular neovascular diseases. Proc Natl Acad Sci U S A. 1996;93:9764-9

100. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol. 2001;155:459-70

101. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin αvβ3 during angiogenesis. J Clin Invest. 1996;98:426-33

102. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin αvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol. 1998;140:1255-63

103. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ. et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin αvβ3. Clin Cancer Res. 2000;6:3056-61

104. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD. et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007;25:1651-7

105. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol. 2007;25:1637-8

106. Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD. et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med. 2009;15:392-400

107. Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all αv integrins. Cell. 1998;95:507-19

108. Lacy-Hulbert A, Smith AM, Tissire H, Barry M, Crowley D, Bronson RT. et al. Ulcerative colitis and autoimmunity induced by loss of myeloid αv integrins. Proc Natl Acad Sci U S A. 2007;104:15823-8

109. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X. et al. Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nat Med. 2002;8:27-34

110. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, Rayburn H, Crowley D, Ullman-Cullere M. et al. β3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999;103:229-38

111. Weis SM, Lindquist JN, Barnes LA, Lutu-Fuga KM, Cui J, Wood MR. et al. Cooperation between VEGF and β3 integrin during cardiac vascular development. Blood. 2007;109:1962-70

112. Mahabeleshwar GH, Feng W, Phillips DR, Byzova TV. Integrin signaling is critical for pathological angiogenesis. J Exp Med. 2006;203:2495-507

113. Hodivala-Dilke KM, Reynolds AR, Reynolds LE. Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res. 2003;314:131-44

114. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008;8:604-17

115. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 1995;270:1500-2

116. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024-8

117. Criscuoli ML, Nguyen M, Eliceiri BP. Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood. 2005;105:1508-14

118. Huang X, Griffiths M, Wu J, Farese RVJr, Sheppard D. Normal development, wound healing, and adenovirus susceptibility in β5-deficient mice. Mol Cell Biol. 2000;20:755-9

119. Breuss JM, Gillett N, Lu L, Sheppard D, Pytela R. Restricted distribution of integrin β6 mRNA in primate epithelial tissues. J Histochem Cytochem. 1993;41:1521-7

120. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF. et al. Expression of the β6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci. 1995;108( Pt 6):2241-51

121. Hakkinen L, Hildebrand HC, Berndt A, Kosmehl H, Larjava H. Immunolocalization of tenascin-C, α9 integrin subunit, and αvβ6 integrin during wound healing in human oral mucosa. J Histochem Cytochem. 2000;48:985-98

122. Huang X, Wu J, Spong S, Sheppard D. The integrin αvβ6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin. J Cell Sci. 1998;111( Pt 15):2189-95

123. Thomas GJ, Poomsawat S, Lewis MP, Hart IR, Speight PM, Marshall JF. αvβ6 Integrin upregulates matrix metalloproteinase 9 and promotes migration of normal oral keratinocytes. J Invest Dermatol. 2001;116:898-904

124. Thomas GJ, Hart IR, Speight PM, Marshall JF. Binding of TGF-β1 latency-associated peptide (LAP) to αvβ6 integrin modulates behaviour of squamous carcinoma cells. Br J Cancer. 2002;87:859-67

125. Zambruno G, Marchisio PC, Marconi A, Vaschieri C, Melchiori A, Giannetti A. et al. Transforming growth factor-β1 modulates β1 and β5 integrin receptors and induces the de novo expression of the αvβ6 heterodimer in normal human keratinocytes: implications for wound healing. J Cell Biol. 1995;129:853-65

126. Koivisto L, Larjava K, Hakkinen L, Uitto VJ, Heino J, Larjava H. Different integrins mediate cell spreading, haptotaxis and lateral migration of HaCaT keratinocytes on fibronectin. Cell Adhes Commun. 1999;7:245-57

127. Kawashima A, Tsugawa S, Boku A, Kobayashi M, Minamoto T, Nakanishi I. et al. Expression of αv integrin family in gastric carcinomas: increased αvβ6 is associated with lymph node metastasis. Pathol Res Pract. 2003;199:57-64

128. Sipos B, Hahn D, Carceller A, Piulats J, Hedderich J, Kalthoff H. et al. Immunohistochemical screening for β6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology. 2004;45:226-36

129. Jones J, Watt FM, Speight PM. Changes in the expression of αv integrins in oral squamous cell carcinomas. J Oral Pathol Med. 1997;26:63-8

130. Ahmed N, Riley C, Rice GE, Quinn MA, Baker MS. αvβ6 integrin-A marker for the malignant potential of epithelial ovarian cancer. J Histochem Cytochem. 2002;50:1371-80

131. Arihiro K, Kaneko M, Fujii S, Inai K, Yokosaki Y. Significance of α9β1 and αvβ6 integrin expression in breast carcinoma. Breast Cancer. 2000;7:19-26

132. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H. et al. Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest. 2005;115:339-47

133. Agrez M, Chen A, Cone RI, Pytela R, Sheppard D. The αvβ6 integrin promotes proliferation of colon carcinoma cells through a unique region of the β 6 cytoplasmic domain. J Cell Biol. 1994;127:547-56

134. Morgan MR, Thomas GJ, Russell A, Hart IR, Marshall JF. The integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9. J Biol Chem. 2004;279:26533-9

135. Niu J, Dorahy DJ, Gu X, Scott RJ, Draganic B, Ahmed N. et al. Integrin expression in colon cancer cells is regulated by the cytoplasmic domain of the β6 integrin subunit. Int J Cancer. 2002;99:529-37

136. Ahmed N, Pansino F, Clyde R, Murthi P, Quinn MA, Rice GE. et al. Overexpression of αvβ6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis. 2002;23:237-44

137. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J. et al. The integrin αvβ6 binds and activates latent TGF β1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96:319-28

138. Hamidi S, Salo T, Kainulainen T, Epstein J, Lerner K, Larjava H. Expression of αvβ6 integrin in oral leukoplakia. Br J Cancer. 2000;82:1433-40

139. Thomas GJ, Nystrom ML, Marshall JF. αvβ6 integrin in wound healing and cancer of the oral cavity. J Oral Pathol Med. 2006;35:1-10

140. Falcioni R, Antonini A, Nistico P, Di Stefano S, Crescenzi M, Natali PG. et al. α6β4 and α6β1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res. 1997;236:76-85

141. Hemler ME, Crouse C, Sonnenberg A. Association of the VLA α6 subunit with a novel protein. A possible alternative to the common VLA β1 subunit on certain cell lines. J Biol Chem. 1989;264:6529-35

142. Wilhelmsen K, Litjens SH, Sonnenberg A. Multiple functions of the integrin α6β4 in epidermal homeostasis and tumorigenesis. Mol Cell Biol. 2006;26:2877-86

143. Dowling J, Yu QC, Fuchs E. β4 integrin is required for hemidesmosome formation, cell adhesion and cell survival. J Cell Biol. 1996;134:559-72

144. Geerts D, Fontao L, Nievers MG, Schaapveld RQ, Purkis PE, Wheeler GN. et al. Binding of integrin α6β4 to plectin prevents plectin association with F-actin but does not interfere with intermediate filament binding. J Cell Biol. 1999;147:417-34

145. Koster J, Geerts D, Favre B, Borradori L, Sonnenberg A. Analysis of the interactions between BP180, BP230, plectin and the integrin α6β4 important for hemidesmosome assembly. J Cell Sci. 2003;116:387-99

146. Sterk LM, Geuijen CA, Oomen LC, Calafat J, Janssen H, Sonnenberg A. The tetraspan molecule CD151, a novel constituent of hemidesmosomes, associates with the integrin α6β4 and may regulate the spatial organization of hemidesmosomes. J Cell Biol. 2000;149:969-82

147. Shaw LM, Rabinovitz I, Wang HH, Toker A, Mercurio AM. Activation of phosphoinositide 3-OH kinase by the α6β4 integrin promotes carcinoma invasion. Cell. 1997;91:949-60

148. Mariotti A, Kedeshian PA, Dans M, Curatola AM, Gagnoux-Palacios L, Giancotti FG. EGF-R signaling through Fyn kinase disrupts the function of integrin α6β4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion. J Cell Biol. 2001;155:447-58

149. Yoon CS, Kim KD, Park SN, Cheong SW. α6 Integrin is the main receptor of human papillomavirus type 16 VLP. Biochem Biophys Res Commun. 2001;283:668-73

150. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-14

151. Rose DM, Alon R, Ginsberg MH. Integrin modulation and signaling in leukocyte adhesion and migration. Immunol Rev. 2007;218:126-34

152. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol. 2005;6:1182-90

153. Anderson DC, Springer TA. Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. Annu Rev Med. 1987;38:175-94

154. Carman CV, Springer TA. Integrin avidity regulation: are changes in affinity and conformation underemphasized?. Curr Opin Cell Biol. 2003;15:547-56

155. Alon R, Feigelson S. From rolling to arrest on blood vessels: leukocyte tap dancing on endothelial integrin ligands and chemokines at sub-second contacts. Semin Immunol. 2002;14:93-104

156. Alon R, Dustin ML. Force as a facilitator of integrin conformational changes during leukocyte arrest on blood vessels and antigen-presenting cells. Immunity. 2007;26:17-27

157. Katagiri K, Imamura M, Kinashi T. Spatiotemporal regulation of the kinase Mst1 by binding protein RAPL is critical for lymphocyte polarity and adhesion. Nat Immunol. 2006;7:919-28

158. Kinashi T. Intracellular signalling controlling integrin activation in lymphocytes. Nat Rev Immunol. 2005;5:546-59

159. Borriello G, Prosperini L, Luchetti A, Pozzilli C. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol. 2009;13:67-71

160. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH. et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-13

161. Chavakis T, Hussain M, Kanse SM, Peters G, Bretzel RG, Flock JI. et al. Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes. Nat Med. 2002;8:687-93

162. Koivunen E, Ranta TM, Annila A, Taube S, Uppala A, Jokinen M. et al. Inhibition of β2 integrin-mediated leukocyte cell adhesion by leucine-leucine-glycine motif-containing peptides. J Cell Biol. 2001;153:905-16

163. Stefanidakis M, Ruohtula T, Borregaard N, Gahmberg CG, Koivunen E. Intracellular and cell surface localization of a complex between αMβ2 integrin and promatrix metalloproteinase-9 progelatinase in neutrophils. J Immunol. 2004;172:7060-8

164. Choi EY, Chavakis E, Czabanka MA, Langer HF, Fraemohs L, Economopoulou M. et al. Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science. 2008;322:1101-4

165. Mousa SA. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Curr Opin Chem Biol. 2002;6:534-41

166. Mullamitha SA, Ton NC, Parker GJ, Jackson A, Julyan PJ, Roberts C. et al. Phase I evaluation of a fully human anti-αv integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res. 2007;13:2128-35

167. Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF. et al. In vivo therapy of malignant melanoma by means of antagonists of αv integrins. Int J Cancer. 2000;87:716-23

168. O'Connor P. Natalizumab and the role of α4-integrin antagonism in the treatment of multiple sclerosis. Expert Opin Biol Ther. 2007;7:123-36

169. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A. et al. N-Methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists. J Med Chem. 1999;42:3033-40

170. Belvisi L, Bernardi A, Colombo M, Manzoni L, Potenza D, Scolastico C. et al. Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids. Bioorg Med Chem. 2006;14:169-80

171. Kumar CC, Malkowski M, Yin Z, Tanghetti E, Yaremko B, Nechuta T. et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual αvβ3 and αvβ5 integrin receptor antagonist. Cancer Res. 2001;61:2232-8

172. Byron A, Humphries JD, Askari JA, Craig SE, Mould AP, Humphries MJ. Anti-integrin monoclonal antibodies. J Cell Sci. 2009;122:4009-11

173. Cai W, Zhang X, Wu Y, Chen X. A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of αvβ3 integrin expression. J Nucl Med. 2006;47:1172-80

174. Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L. et al. 64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor αvβ3 integrin expression. J Nucl Med. 2007;48:1162-71

175. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL. et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin α(v)β3 expression in man. Clin Cancer Res. 2006;12:3942-9

176. Leong-Poi H, Christiansen J, Klibanov AL, Kaul S, Lindner JR. Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to αv-integrins. Circulation. 2003;107:455-60

177. Wang H, Chen K, Cai W, Li Z, He L, Kashefi A. et al. Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein. Mol Cancer Ther. 2008;7:1044-53

178. Somanath PR, Malinin NL, Byzova TV. Cooperation between integrin αvβ3 and VEGFR2 in angiogenesis. Angiogenesis. 2009;12:177-85

179. Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL. Transforming growth factor β induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res. 2009;69:475-82

180. Morozevich G, Kozlova N, Cheglakov I, Ushakova N, Berman A. Integrin α5β1 controls invasion of human breast carcinoma cells by direct and indirect modulation of MMP-2 collagenase activity. Cell Cycle. 2009;8:2219-25

181. Maupas-Schwalm F, Bedel A, Auge N, Grazide MH, Mucher E, Thiers JC. et al. Integrin αvβ3, metalloproteinases, and sphingomyelinase-2 mediate urokinase mitogenic effect. Cell Signal. 2009;21:1925-34

182. Orr AW, Ginsberg MH, Shattil SJ, Deckmyn H, Schwartz MA. Matrix-specific suppression of integrin activation in shear stress signaling. Mol Biol Cell. 2006;17:4686-97

183. Diaz-Gonzalez F, Forsyth J, Steiner B, Ginsberg MH. Trans-dominant inhibition of integrin function. Mol Biol Cell. 1996;7:1939-51

184. Dibya D, Sander S, Smith EA. Identifying cytoplasmic proteins that affect receptor clustering using fluorescence resonance energy transfer and RNA interference. Anal Bioanal Chem. 2009;395(7):2303-11

185. Chigaev A, Buranda T, Dwyer DC, Prossnitz ER, Sklar LA. FRET detection of cellular α4-integrin conformational activation. Biophys J. 2003;85:3951-62

186. Chen X. Multimodality imaging of tumor integrin αvβ3 expression. Mini Rev Med Chem. 2006;6:227-34

Author contact

Corresponding address Corresponding author: Dr. Xiaoyuan Chen, Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Health (NIH) , 31 Center Dr, 31/1C22, Bethesda, MD 20892, USA; Tel: 301-451-4246; Email: shawn.chengov


Published 2011-1-16